Search

Displaying results 8291 - 8300 of 10000 in total
  1. Drug

    Mephenytoin

    go.drugbank.com/drugs/DB00532
    ApprovedWithdrawn

    These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.

  2. Drug

    Ledaborbactam etzadroxil

    go.drugbank.com/drugs/DB21455
    Investigational

    The usage of the INN stem '-bactam' in the name indicates that Ledaborbactam etzadroxil is a ẞ-lactamase inhibitor. … Ledaborbactam etzadroxil is under investigation in clinical trial NCT06733675 (Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination).

  3. Drug

    Vevorisertib

    go.drugbank.com/drugs/DB21481
    Investigational

    Vevorisertib is under investigation in clinical trial NCT02761694 (Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations … The usage of the INN stem '-sertib' in the name indicates that Vevorisertib is a serine/threonine kinase inhibitor.

  4. Drug

    Elsulfavirine

    go.drugbank.com/drugs/DB14929
    Investigational

    Elsulfavirine is under investigation in clinical trial NCT03706898 (Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food

  5. Drug

    DTX-101

    go.drugbank.com/drugs/DB17699
    Investigational

    DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene.

  6. Drug

    Risovalisib

    go.drugbank.com/drugs/DB21474
    Investigational

    Risovalisib is under investigation in clinical trial NCT05043922 (A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma).

  7. Drug

    Macozinone

    go.drugbank.com/drugs/DB14821
    Investigational

    Macozinone is under investigation in clinical trial NCT03036163 (Phase 1 Study of PBTZ169).

  8. Drug

    JQ1

    go.drugbank.com/drugs/DB17021
    Experimental

    First-in-class potent and selective inhibitor of the BRD4 signaling pathway.[A252967]

  9. Drug

    NKX101

    go.drugbank.com/drugs/DB18131
    Investigational

    NKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.

    Synonyms: a fourth generation activating chimeric receptor (ACR) natural killer (NK) cell therapy engineered with an NKG2D ACR, OX40 costimulatory domain, CD3zeta signaling moiety, and membrane bound IL-15 (mb-IL15
  10. Drug

    MSX-122

    go.drugbank.com/drugs/DB12715
    Investigational

    MSX-122 has been used in trials studying the treatment of Solid Tumors.